Valeant Pharmaceuticals International, Inc. / Sanitas

Branded Generics & OTC (Dermatology, Hospital Injectables, Ophthalmology) — Central & Eastern Europe

$137M Sanitas projected 2011 revenue (>€100M / >$137M) per Valeant deal disclosure

Disease Overview

Branded generics serve everyday primary-care indications (dermatology, anti-infectives, ophthalmology, hospital injectables) where physician/pharmacist brand familiarity drives durable share even after molecule patent expiry. In Central and Eastern Europe, where reimbursement penetration is uneven and out-of-pocket payment is high, branded generics historically command pricing power versus pure commodity generics.

Competitive Landscape

The 2011 CEE branded-generics field was led by Teva (post-Ratiopharm), Sandoz/Novartis, Zentiva (Sanofi), Polpharma, KRKA, Gedeon Richter, Stada and Egis. Valeant under CEO Mike Pearson had been executing a roll-up strategy of branded specialty pharma assets (Biovail merger 2010, prior PharmaSwiss acquisition for CEE entry) and had just lost a bidding contest for Cephalon to Teva. Sanitas — Lithuanian-headquartered, Kaunas-based, ~390 SKUs across 9 CEE countries (anchor markets Poland, Russia, Lithuania) with strength in dermatology, ophthalmology and hospital injectables and ~80% non-reimbursed mix — fit Valeant's playbook of low-government-pricing-exposure assets. Pearson called out dermatology and hospital injectables as the explicit strategic targets, layering onto Valeant's existing dermatology footprint. The deal was structured as 87.2% upfront from majority holders plus a mandatory tender offer for the float, closing Q3-Q4 2011. It became part of the broader Valeant CEE/EM platform that the post-2015 reorganized Bausch Health later carried (now under the Bausch + Lomb / Bausch Health corporate parent referenced in the deal record).